RE: RE: RE: SHS I read your and "sanduf" comments. This what happens with SHS is very comparable with what was going on with the NPC. Both are Vancouver biotechs, both are successful with there research, ok they are working in 2 completely different areas. I am comparing them on following levels: both have a very good business team, they successful in their research, their stocks are in the same price level (between $0.20 and $ 0.50) Just NPC is very close to their FDA results (they finalized the phase III). NPC during their phase III clinical tests they also run short of money, their stock headed also down to a below $0.20 level and the insiders at $0.25 purchased 40 million shares not only to finance their need to complete the last step of phase III but to get
CONTROL OF THE COMPANY......for a bargain price. Within a month they will probably get as well the approval of their drug; resulting in a jump of value. If same thing will happen with SHS, then you will see next action that they will offer a huge amount of shares at very low price which insiders will buy most or all of them. Because they want to make most of the profits. Then most likely when it comes closer to the final of the phase III the stock price will go much higher, if they get it approved price will multiply in value.
what is important for the individual investor:.....to watch what happens with the clinical progress and if they offer a huge amont of shares and who buys them. Warburg is experienced in getting new drugs approved, watch their actions. An indication at which level to buy shares at the open market is where the insiders are buying....
this is just my view.